Navigation

Cancer drugs save Roche from weak Tamiflu sales

The pharmaceutical giant Roche has announced a marginal rise in third-quarter revenue on demand for the company's Avastin and Herceptin cancer medications.

This content was published on October 21, 2008 - 09:40

The Basel-based firm, which reports profit figures for the half year and full year, said sales had risen to SFr11.3 billion ($9.83 billion) from SFr11.12 billion the same time last year.

"We again expect a good full-year result and confirm our outlook for 2008," said Severin Schwan, the company's chief executive.

However, the nine-month total for the drugmaker stood at SFr33.3 billion, a two per cent drop, on the decline in sales of the antiviral Tamiflu, which fell 69 per cent to SFr428 million for the period.

Roche also confirmed it would be moving ahead with a $43.7 billion bid for the rest of California-based Genentech, the company which developed its two best-selling cancer drugs.

Roche currently owns 56 per cent of Genentech and a full takeover would give it control of all revenues for its profitable drugs. In July, Genentech rejected Roche's offer of $89 per share, saying it was undervalued.

This article was automatically imported from our old content management system. If you see any display errors, please let us know: community-feedback@swissinfo.ch

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

Share this story

Change your password

Do you really want to delete your profile?